第IA期肺腺癌病患術後復發之預後因子

洪榮志

《臨床醫學月刊》 81卷5期 (2018/05) Pp. 270-273

https://doi.org/10.6666/ClinMed.201805_81(5).0048

摘要

肺癌是全世界癌症死亡的主要原因。近來由於胸部電腦斷層掃描篩檢的增加，肺腺癌似乎有越來越多的趨勢。第IA期肺腺癌是相當早期的肺腺癌，手術切除的治療效果很好。但是即使是第IA期或小於三公分淋巴結陰性的肺癌，腫瘤復發仍是手術切除後治療失敗的主要原因。肺腺癌新的組織學分類法具有顯著的預後價值，微乳頭型和實體型病患具有較差的預後。肺腺癌組織學新分類法亦與病患之縱膈腔淋巴結轉移具有顯著的相關性。針對第IA期或小於三公分淋巴結陰性的肺癌，除了性別與腫瘤大小之外，肺腺癌組織學亞型也是這些病患無復發存活串的顯著預後因子。是否針對微乳頭/實體型為主的第IA期肺腺癌病患給予輔助治療，是未來臨床試驗研究的方向，並將有助於進一步提升肺腺癌病患之治療成果。

關鍵字

肺腺癌(lung adenocarcinoma) ； 組織學(histology) ； 預後(prognosis) ； 復發(recurrence) ； 存活率(survival)

參考文獻

Zhang J, Wu J, Tan Q, et al. Why do pathological stage IA lung adenocarcinomas vary from prognosis? A clinicopathologic study of 176 patients with pathological stage IA lung adenocarcinoma based on the IASLC/ATS/ERS classification. J Thorac Oncol 2

Sasada S, Nakayama H, Miyata Y, et al. Comparison of malignant grade between pure and partially invasive types of early lung adenocarcinoma. Ann Thorac Surg 2015;99:956-60.

Yoshiya T, Mimae T, Tsutani Y, et al. Prognostic Role of Subtype Classification in Small-Sized Pathologic N0 Invasive Lung Adenocarcinoma. Ann Thorac Surg 2016;102:1668-73.

Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011;6:244

Yoshizawa A, Motoi N, Riely GJ, et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: Prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol 2011;24:653-64.